The analysis published in 2019 included five RCTs involving 138/125 participants with DCM, which revealed that compared with control groups (placebo/NA), atorvastatin treatment could reduce CRP levels (SMD: −0.47; 95% CI: −0.72 to −0.22; P = 0.0003; AMSTAR 7; Evidence class IV; Figure 3) significantly. This evidence concerns the gene CRP and familial dilated cardiomyopathy.